$NVO News and Market Events
Every $NVO story Market Flux has tracked.
- Unusual Volume
Novo Nordisk Stock Falls Up to 7.4% as 2030 Strategy and $23 Billion Pipeline Target Disappoint Investors
Novo Nordisk shares plunged as much as 7.4% on Monday after CEO Mike Doustdar used a Capital Markets Day in London to lay out a long-term growth strategy that failed to calm investor…
- Market Flux Event
FDA Accepts Cogent Biosciences NDA for Bezuclastinib as Novo Nordisk Rebrands Amid Lilly Competition
Cogent Biosciences secured a key regulatory milestone as the FDA accepted its New Drug Application for bezuclastinib in patients with Advanced Systemic Mastocytosis, assigning a PDUFA…
- Market Flux Event
Eli Lilly Wins European Approval for Weight Loss Pill Foundayo as BMY Scores FDA Nod for Myeloma Drug
Eli Lilly secured the first European regulatory approval for its oral weight loss pill Foundayo in the United Kingdom, intensifying a direct battle with Novo Nordisk, whose oral Wegovy was…
- Top Mover
Eli Lilly's Oral Weight-Loss Pill Foundayo Wins First European Approval in the UK
Britain's Medicines and Healthcare products Regulatory Agency approved Eli Lilly's oral GLP-1 pill orforglipron, branded Foundayo, on August 10, making the UK the first European country to…
- Market Flux Event
Eli Lilly Wins UK Approval for Oral Weight-Loss Pill Foundayo as Biotech Sector Sees Wave of Catalysts
Eli Lilly's oral weight-loss pill orforglipron, branded Foundayo, secured its first European regulatory approval in Britain on August 10, extending the drug's commercial footprint beyond…